1. Home
  2. AMRC vs MNKD Comparison

AMRC vs MNKD Comparison

Compare AMRC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ameresco Inc.

AMRC

Ameresco Inc.

HOLD

Current Price

$25.65

Market Cap

1.2B

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.11

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRC
MNKD
Founded
2000
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2010
2004

Fundamental Metrics

Financial Performance
Metric
AMRC
MNKD
Price
$25.65
$4.11
Analyst Decision
Strong Buy
Buy
Analyst Count
8
8
Target Price
$37.88
$8.69
AVG Volume (30 Days)
640.3K
4.8M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,769,928,000.00
$348,966,000.00
Revenue This Year
$10.71
$35.81
Revenue Next Year
$9.07
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$18.38
$2.23
52 Week High
$44.93
$6.51

Technical Indicators

Market Signals
Indicator
AMRC
MNKD
Relative Strength Index (RSI) 54.05 45.88
Support Level $24.73 $3.78
Resistance Level $33.03 $3.94
Average True Range (ATR) 1.86 0.22
MACD 0.71 -0.02
Stochastic Oscillator 52.93 20.18

Price Performance

Historical Comparison
AMRC
MNKD

About AMRC Ameresco Inc.

Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: